A Pilot Study of Hypertension in Breast Cancer Patients Receiving Bevacizumab
- Participants will begin this research study within 14 days of starting Bevacizumab,
either as part of standard treatment or as part of another clinical trial.
- Participants will have an ultrasound test done at baseline, and after completion of
their first and second cycles of therapy.
- Vital signs and blood tests will be performed a the start of the study, and after
completion of the first and second cycles of therapy.
Observational Model: Case-Only, Time Perspective: Prospective
To evaluate changes in flow-mediated vasodilation (FMD) from baseline to treatment timepoints in an effort to explore the relationships between exposure to bevacizumab, eNOS activity, and vascular dysfunction.
Erica Mayer, MD MPH
Dana-Farber Cancer Institute
United States: Institutional Review Board
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|